- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Acute myeloid leukaemia
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1123KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 214KB)
Venetoclax – July 2021
Venetoclax: Tablet 50 mg, Tablet 100 mg: Venclexta®
Last updated
29 October 2021